By Fineline Cube China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million in Tianjin Jikun Medical Technology Co., Ltd. (“Jikun Medical”), deepening its strategic footprint in the organ fibrosis field. Upon completion, Baheal Pharma will hold a 25.4399% equity stake in Jikun Medical, reinforcing its commitment to fibrosis-focused therapeutics including the lead candidate JK1033.
Deal Overview & Strategic Terms
| Item | Detail |
|---|---|
| Investor | Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) |
| Target | Tianjin Jikun Medical Technology Co., Ltd. |
| Investment Size | RMB 40 million (follow-on investment) |
| Post-Deal Equity Stake | 25.4399% |
| Announcement Date | 29 Aug 2026 |
| Use of Proceeds | R&D of JK1033 (idiopathic pulmonary fibrosis), ADC candidates, other pipelines, and general operations |
Drug Profile & Pipeline – JK1033 and ADC Candidates
- Lead Molecule: JK1033, an investigational drug targeting idiopathic pulmonary fibrosis (IPF)
- Indication Focus: IPF — a progressive, life-threatening fibrotic lung disease with high unmet medical need
- Platform Extension: Proceeds also fund antibody-drug conjugate (ADC) candidates, broadening Jikun Medical’s pipeline beyond fibrosis
- Strategic Rights: Under the 2025 cooperation agreement, Baheal Pharma secured priority purchase rights for certain Jikun Medical pharmaceutical products, plus priority negotiation rights for contract manufacturing and global commercialization
Commercial Rationale
- Follow-on Commitment: The transaction builds on Baheal Pharma’s initial 2025 investment in Jikun Medical and an existing strategic cooperation agreement, signaling continued conviction in the partnership
- Fibrosis Expansion: The additional capital strengthens Baheal Pharma’s strategic presence across the organ fibrosis landscape, a therapeutic area with limited treatment options and growing demand
- Vertical Integration: Priority purchase and commercialization rights position Baheal Pharma to capture downstream value from JK1033 and future pipeline assets
- Pipeline Diversification: Funding directed at ADC candidates adds a second growth vector alongside the fibrosis franchise
Market Impact & Outlook
- The investment consolidates Baheal Pharma’s role as a key strategic backer of Jikun Medical, with a meaningful 25.4399% minority stake
- Progress of JK1033 will be the near-term catalyst to watch, given IPF’s significant unmet need in China and globally
- The combined fibrosis + ADC pipeline broadens optionality for both companies and may support future licensing or co-development deals
- Deeper capital and commercial ties are expected to accelerate clinical advancement of Jikun Medical’s lead programs
Forward‑Looking Statements — This brief contains forward-looking statements regarding investment plans, pipeline development, and strategic cooperation that involve risks and uncertainties. Actual results may differ materially. Nothing herein constitutes investment advice.-Fineline Info & Tech